Bipolar disorder due to another medical condition is a diagnosis reserved for prominent and persistent mood elevation, expansiveness, or irritability that arises as the direct pathophysiological consequence of an identifiable medical illness rather than a primary mood disorder. The clinical stakes are high because the — historically called — can be the presenting feature of stroke, traumatic brain injury, multiple sclerosis, neurosyphilis, autoimmune encephalitis, HIV, Cushing syndrome, or hyperthyroidism, and missing the underlying cause means missing the treatment that matters most. codes the same construct under 6A60.4, secondary mood syndrome with manic symptoms. Compared with primary , late or atypical age of onset, focal neurologic findings, cognitive impairment out of proportion to mood, and a temporal lock to a new medical event are the features that should redirect the workup. Management has two parallel tracks: treat the underlying condition and control the mood syndrome, usually with cautious mood stabilization or atypical antipsychotics chosen against the patient's medical comorbidity. The bottom line — when looks wrong for the patient, suspect a medical cause and investigate before committing to a primary bipolar diagnosis.
Population-level prevalence figures are unreliable because the diagnosis is operationally defined by an identified medical cause, and case-finding depends entirely on workup intensity. The literature is dominated by clinic-based series, neurology cohorts, and case reports rather than community surveys.1-2
Frequency in clinical samples
- In stroke cohorts, secondary mania is uncommon, with most series reporting prevalence below 2%, contrasted with post-stroke depression rates above 30%.3
- After traumatic brain injury, manic syndromes have been described in roughly 1-9% of patients depending on severity and follow-up duration, with higher rates after right-hemisphere or orbitofrontal injury.4
- Multiple sclerosis has a higher rate of bipolar-spectrum presentations than the general population, estimated at approximately twice the population base rate, although disentangling steroid-induced episodes is difficult.5
- Among patients hospitalized for first-episode mania, several inpatient series suggest that 5-10% have an identifiable secondary cause when systematically investigated.6
Demographic and risk-factor patterns
- Age of onset clusters later than primary bipolar disorder; new-onset mania after age 50 carries an especially high pretest probability of a secondary cause.1,6
- Sex distribution mirrors the underlying medical condition rather than primary bipolar I, which has approximately equal sex ratios.1
- Family history of mood disorder is typically absent, though it does not exclude the diagnosis.6
- Identified risk factors include right-hemisphere lesions (particularly orbitofrontal, basotemporal, and thalamic), neurodegenerative disease, autoimmune CNS illness, endocrinopathy, and HIV.1,3-4
A first manic episode in a patient older than 50 with no prior mood history should prompt a structured medical and neurologic workup before being labeled primary bipolar disorder.1,6
Secondary mania is best understood as a final common pathway: heterogeneous insults converge on right-sided frontolimbic and subcortical circuits that normally constrain mood, drive, and behavior. Lesion localization, neurotransmitter perturbation, and inflammation each contribute depending on the underlying illness.1,7
Lesion-based models
- The classic Robinson and Starkstein lesion-mapping work implicated right orbitofrontal cortex, right basotemporal cortex, and right-sided subcortical structures (caudate, thalamus) in post-stroke and post-traumatic mania.3-4
- Disruption of right-hemisphere networks that modulate the and ventral prefrontal control over limbic structures is the proposed substrate.7
- Bilateral or left-sided lesions produce mania less often, though they are not exempt.3
Neurotransmitter and circuit perturbation
- Dopaminergic hyperactivity in mesolimbic and nigrostriatal pathways is implicated, mirroring the pathophysiology invoked for primary mania and consistent with the manic effects of dopaminergic agents in Parkinson disease.7-8
- Disturbances of serotonergic and noradrenergic tone, particularly in the context of corticosteroid exposure or thyrotoxicosis, are also recognized contributors.8-9
- Inflammatory cytokine elevations and direct CNS autoimmunity (for example anti-NMDA receptor encephalitis) can produce manic and mixed presentations through limbic and frontal involvement.10
Specific medical mechanisms
- Endocrine: hyperthyroidism, Cushing syndrome, and exogenous corticosteroids each produce mood elevation through HPA-axis and monoaminergic effects.8-9
- Infectious: HIV (particularly with CNS involvement or low CD4), neurosyphilis, and herpes simplex encephalitis are recurrent culprits.1,11
- Neurologic: stroke, TBI, multiple sclerosis, brain tumors (frontal and temporal), Huntington disease, and frontotemporal dementia all have documented associations.1,3-5
- Autoimmune: anti-NMDA receptor encephalitis, lupus cerebritis, and Hashimoto encephalopathy can present with manic features.10
- Metabolic: hypercalcemia, B12 deficiency, and uremia are less common but reversible contributors.1
THIS MEs ME UP
Thyroid, HIV, Inflammation/autoimmune, Steroids, Mass lesion, Epilepsy/encephalitis, Stroke, Multiple sclerosis, Endocrine (Cushing), Uremia/metabolic, Parkinson dopaminergic — the medical causes of secondary mania to screen at first presentation.
DSM-5-TR places this diagnosis in the bipolar and related disorders chapter and requires that the mood syndrome be the direct pathophysiological consequence of a medical condition rather than a primary mood disorder, a delirium, or a substance-induced presentation. The criteria are designed to force the clinician to commit to a causal hypothesis grounded in history, examination, and ancillary data.12
DSM-5-TR criteria, summarized
- A prominent and persistent disturbance of mood characterized by elevated, expansive, or irritable mood with or without depressed mood, or markedly diminished interest, dominates the clinical picture.12
- Evidence from history, physical examination, or laboratory findings supports that the disturbance is the direct pathophysiological consequence of another medical condition.12
- The disturbance is not better explained by another mental disorder, including a primary bipolar disorder.12
- The disturbance does not occur exclusively during the course of a delirium.12
- The disturbance causes clinically significant distress or impairment in social, occupational, or other important areas of functioning, or necessitates hospitalization to prevent harm to self or others, or there are psychotic features.12
Specifiers
- With manic features: full criteria for a manic or hypomanic episode are not met.12
- With manic- or hypomanic-like episode: full criteria are met for a manic or hypomanic episode except duration or absence of impairment.12
- With : symptoms of depression are also present but do not predominate.12
Coding convention
- The medical condition is named in the diagnostic statement (for example, bipolar disorder due to multiple sclerosis), and the medical condition is coded separately when documented.12
ICD-11 differences
- ICD-11 codes the construct under 6A60.4 (secondary mood syndrome with manic symptoms) within secondary mental and behavioral syndromes.13
- ICD-11 separates secondary syndromes from the primary bipolar disorder grouping more cleanly than DSM-5-TR, reflecting the etiologic logic.13
A separate diagnosis, , applies when the syndrome is attributable to a substance or medication; corticosteroid- and dopamine-agonist-induced mania belong there, not under bipolar disorder due to another medical condition.12
The mood syndrome resembles primary mania in surface phenomenology but tends to be coloured by the lesion or disease that produced it, with irritability, disinhibition, and confusional features often more salient than classic euphoria. Course tracks the underlying illness rather than a primary cycling pattern.1,7
Symptom presentation
- Elevated, expansive, or irritable mood with increased energy or activity is the cardinal feature, paralleling the affective core of a primary manic episode.12
- Irritability and aggression are often more prominent than euphoria in lesion- and TBI-related cases.4
- Disinhibition, impulsivity, hypersexuality, and pressured speech are common, particularly with orbitofrontal involvement.1,4
- Decreased need for sleep, racing thoughts, and grandiosity occur but may be less consistently reported than in primary mania.1
- Psychotic features, when present, are frequently mood-congruent grandiose or paranoid delusions.1,7
- Cognitive impairment (attention, executive function, memory) often exceeds what is expected in primary mania and can be the clue that redirects the workup.7
Course features that distinguish secondary mania
- Onset is typically temporally locked to the medical event — within days to weeks of a stroke, surgical procedure, infection, or initiation of an offending illness.3-4
- Episode duration parallels the underlying disease course; resolution often follows treatment of the medical cause rather than an independent cycling pattern.1
- Recurrence depends on whether the medical insult is static (stroke, TBI), relapsing-remitting (multiple sclerosis), or progressive (frontotemporal dementia).1,5
- Family history of mood disorder is typically absent, in contrast with primary bipolar I.6
Red flags suggesting a secondary cause
- First episode of mania after age 40, and especially after 50.1,6
- Focal neurologic findings on examination.3
- Confusion, fluctuating attention, or visual (consider delirium or autoimmune encephalitis).10
- Headache, fever, recent infection, or recent neurosurgical procedure.1
- New seizures or movement disorder.10
- Atypical response or sensitivity to standard mood stabilizers.1
Secondary mania can present with prominent confusion or fluctuating attention; if delirium criteria are met, the mood syndrome is not coded as bipolar disorder due to another medical condition until the delirium has cleared and a persistent mood syndrome remains.12
The differential is structured around the question that gates the diagnosis: is the mood syndrome the direct pathophysiological consequence of a medical illness, a substance, a primary psychiatric disorder, or a delirium? Each pathway leads to a different code and a different treatment.12
Primary bipolar I or II disorder
- Earlier age of onset, family history of mood disorder, prior depressive episodes, and absence of a temporally relevant medical event support a primary diagnosis.12,14
- An identified medical condition does not automatically exclude primary bipolar disorder; the clinical question is whether the medical condition is plausibly causal in this episode.12
Substance/medication-induced bipolar and related disorder
- Corticosteroids, levodopa and dopamine agonists, antidepressants, stimulants, anabolic steroids, and interferon are common precipitants.8-9
- Onset during intoxication, initiation, or dose escalation, with resolution after withdrawal, supports this diagnosis.12
Delirium
- Acute onset, fluctuating course, inattention, and disorganized thinking shift the diagnosis to delirium; the mood syndrome is not separately coded while delirium dominates.12,15
- Hyperactive delirium can mimic mania and is the most commonly missed alternative diagnosis on medical wards.15
Major neurocognitive disorder with behavioral disturbance
- Frontotemporal dementia can present with disinhibition, hyperorality, and impulsivity that mimic mania; insidious onset and progressive cognitive decline differentiate it.16
Other psychiatric mimics
- Agitated depression, mixed features, bipolar type, and personality disorder with affective instability share surface features with secondary mania and are differentiated by longitudinal history and absence of a medical etiology.14
Medical mimics worth naming explicitly
- Hyperthyroidism, Cushing syndrome, hyperadrenocorticism, hypercalcemia, B12 deficiency, neurosyphilis, HIV-associated neurocognitive disorder, autoimmune encephalitis (anti-NMDA receptor and limbic encephalitis), neurosarcoidosis, and CNS lupus.1,10-11
- Temporal lobe epilepsy and postictal states can produce manic-like syndromes.1
Assessment is structured to test the causal hypothesis. The history and examination set the pretest probability for a secondary cause, and ancillary studies are ordered targeted to that hypothesis rather than as an undifferentiated panel.1,17
History and examination essentials
- Establish the temporal relationship between the medical event and onset of mood symptoms.1
- Document prior mood episodes, family history of mood disorder, and any prior response to mood stabilizers.14
- Elicit substance and medication history including corticosteroids, dopaminergic drugs, recent antidepressant initiation, immunotherapy, and over-the-counter or herbal stimulants.8-9
- Perform a focused neurologic examination including cranial nerves, motor and sensory testing, gait, and frontal release signs.1
- Screen cognition with a structured tool such as the rather than the MMSE alone, given its greater sensitivity for executive dysfunction.18
Standard initial laboratory workup
- CBC, comprehensive metabolic panel, calcium, magnesium, phosphate, TSH with free T4, B12, folate, urinalysis, and urine toxicology.1,17
- HIV testing and syphilis serology in unexplained new-onset mania, particularly with neurologic findings.1,11
- Pregnancy test in patients of childbearing potential before initiating teratogenic agents.19
Targeted second-tier workup
- Neuroimaging with MRI brain (preferred over CT) for first-episode mania at atypical age, focal findings, or suspected demyelinating, neoplastic, or vascular disease.1,17
- Electroencephalogram if seizure or encephalopathy is suspected.10
- Lumbar puncture with cell count, protein, glucose, and autoimmune encephalitis panel (including anti-NMDA receptor antibodies) when encephalitis is on the differential.10
- ANA, complement, and additional autoimmune serologies when systemic autoimmune disease is suspected.10
- 24-hour urinary cortisol or overnight dexamethasone suppression test if Cushing syndrome is plausible.9
Validated rating scales for symptom tracking
- (YMRS) for mania severity and treatment response.20
- (CARS-M) when mixed and psychotic features are prominent.20
- Bech-Rafaelsen Mania Scale as an alternative measure used in inpatient research.20
What not to order
- Routine ceruloplasmin, porphyrin screens, or whole-genome panels in the absence of suggestive features add cost without changing management.17
Begin every workup by asking what new about this patient's medicine, brain, or body coincided with the onset of mood symptoms; the answer often points to the diagnosis before any test is ordered.1
Treatment runs on two tracks in parallel: address the underlying medical condition, and control the mood syndrome with the lowest effective dose of agents chosen against the patient's medical comorbidity. The evidence base is dominated by case series and small open studies; randomized data specific to bipolar disorder due to another medical condition are sparse.1,21
Pharmacotherapy
- Treatment of the underlying medical cause — for example, normalizing thyroid function, reducing or tapering corticosteroids, treating CNS infection, or initiating immunotherapy for autoimmune encephalitis — is the first priority and may be sufficient on its own.1,10
- Atypical antipsychotics are commonly used as first-line symptom control because of rapid onset, broad efficacy in mania, and tolerability in medically complex patients; quetiapine, olanzapine, risperidone, and aripiprazole are the most frequently chosen agents.21-22
- Limited evidence suggests that mood stabilizers including valproate and can be effective, but each requires careful weighing of the medical context.21-22
- Valproate is often preferred over lithium in post-stroke and post-TBI mania because of its tolerability profile, though hepatotoxicity and thrombocytopenia warrant monitoring.4,21
- Lithium is effective but its narrow therapeutic window of 0.6-1.2 mEq/L for maintenance, renal clearance, and neurotoxicity in CNS-injured patients limit its use; it should be avoided when renal function is unstable.19,22
- Carbamazepine and oxcarbazepine are options, particularly when seizure risk coexists, but drug interactions and hyponatremia must be tracked.21
- (lorazepam, clonazepam) are useful adjuncts for acute agitation and sleep, time-limited.21
- Antidepressants should generally be discontinued or avoided during the manic phase regardless of the etiology.14
Lithium has a narrow therapeutic window (0.6-1.2 mEq/L for maintenance) and is renally cleared; it requires baseline and ongoing monitoring of renal function, thyroid function, and drug levels, and is poorly tolerated in patients with cerebral injury or unstable fluid status.19,22
Psychotherapy
- Limited evidence directly addresses psychotherapy for secondary mania; pragmatic supportive psychoeducation for patients and families about the medical etiology is appropriate.1
- Cognitive rehabilitation is reasonable when persistent cognitive sequelae of the underlying neurologic illness contribute to functional impairment.7
Neuromodulation
- is effective for severe, treatment-refractory, or catatonic presentations and has been used successfully in secondary mania, particularly when pharmacotherapy is poorly tolerated.23
- is also an option when acute pharmacologic management is contraindicated by the underlying medical illness, with appropriate anesthetic and medical clearance.23
- Limited evidence is available for in this indication; it is not a standard treatment.23
Adjunctive
- Environmental modification including reduced stimulation, consistent staff, and one-to-one observation reduces escalation in agitated medically ill patients.15
- Address sleep disruption directly, since sleep loss can perpetuate the manic syndrome independent of the medical cause.14
- Coordinate care between psychiatry and the primary medical service; consultation-liaison involvement throughout the admission is standard practice.1
| Intervention | Evidence base/Comparator | Benefits | Harms | Certainty | Notes |
|---|---|---|---|---|---|
| Treatment of underlying medical cause | Case series, mechanistic reasoning | Resolution of mood syndrome in many cases when reversible cause addressed | Depends on the disease-specific therapy | low | First-line; etiologic logic of the diagnosis |
| Atypical antipsychotics (quetiapine, olanzapine, risperidone, aripiprazole) | Open trials and case series; extrapolation from primary mania RCTs | Reduction of manic symptoms within days; broad coverage of agitation and psychosis | Sedation, metabolic effects, EPS, QT prolongation | low | Most commonly used symptom-control class in case series |
| Valproate | Open trials and case series in post-stroke and TBI mania | Reduction of manic symptoms; favorable in seizure-prone patients | Hepatotoxicity, thrombocytopenia, teratogenicity, weight gain | low | Often preferred over lithium in CNS-injured patients |
| Lithium | Extrapolation from primary mania; case reports in secondary mania | Effective antimanic; reduces suicide risk in primary bipolar | Narrow therapeutic window, renal and thyroid effects, neurotoxicity | very_low | Use cautious; avoid in unstable renal function or fluctuating volume status |
| Carbamazepine / oxcarbazepine | Case series; antiepileptic crossover | Antimanic effect; useful when seizures coexist | Hyponatremia, drug interactions, rash | very_low | Reasonable when seizure risk is present |
| Benzodiazepines (adjunctive) | Clinical practice; small studies | Acute agitation and insomnia control | Sedation, falls, delirium worsening, dependence | low | Time-limited adjunct only |
| Electroconvulsive therapy | Case series | Effective in severe, refractory, or pharmacologically constrained cases | Cognitive effects, anesthetic risk | low | Reasonable when pharmacotherapy fails or is contraindicated |
The harms profile in this population is amplified by medical comorbidity, polypharmacy, and the overlap between psychiatric medication side effects and signs of the underlying illness. The evidence base itself has substantial limitations.1,21
Common adverse effects to anticipate
- Atypical antipsychotic side effects in medically ill patients include sedation, orthostasis, metabolic disturbance, and extrapyramidal symptoms; older patients with neurologic disease are particularly vulnerable.22
- Valproate-associated hepatotoxicity, thrombocytopenia, and pancreatitis can be silent in the early phase and require scheduled monitoring.21
- Lithium can produce tremor, polyuria, and cognitive blunting at therapeutic levels and overt neurotoxicity at supratherapeutic levels, with a narrower margin in CNS-injured patients.22
Serious or rare adverse effects
- and are uncommon but life-threatening; risk is elevated by polypharmacy.22
- Carbamazepine-induced Stevens-Johnson syndrome has a strong association with HLA-B*1502 in patients of Asian ancestry; pharmacogenetic screening is recommended in that population before initiation.24
- Lithium toxicity can be precipitated by dehydration, NSAIDs, ACE inhibitors, and thiazide diuretics — a frequent combination in medically ill older patients.22
- ECT in patients with recent stroke, raised intracranial pressure, or unstable cardiopulmonary disease requires careful risk-benefit weighing.23
Monitoring, withdrawal, and discontinuation
- Lithium requires baseline TSH, renal function, calcium, and EKG, then ongoing levels and renal monitoring during titration and at steady state.19,22
- Valproate requires baseline LFTs, CBC with platelets, and pregnancy testing, with monitoring during titration.19
- Antipsychotics warrant baseline and serial metabolic monitoring (weight, lipids, glucose), and EKG in patients with cardiac risk factors.22
- Discontinuation of an effective agent should be gradual and tied to resolution or stabilization of the underlying illness rather than an arbitrary timeline.1
Limitations of the evidence base
- The literature is dominated by case reports, case series, and open trials, with very few randomized controlled trials specific to bipolar disorder due to another medical condition.1,21
- Heterogeneity of underlying medical causes makes pooled analysis difficult and limits external validity.1
- Publication bias likely overstates response rates in case series.21
- Long-term outcome data, including recurrence rates and functional trajectories, are sparse.1
Underlying medical illness shapes both presentation and treatment selection in identifiable subgroups. Disease-specific considerations should drive medication choice more than disorder-specific guidelines.1
Older adults
- New-onset mania after age 50 has a high pretest probability of a secondary cause and warrants a structured medical and neurologic workup.1,6
- Antipsychotics carry a black-box warning for increased mortality in older adults with dementia-related psychosis; this warning extends to off-label use in behavioral disturbances of major neurocognitive disorder.22,25
- Lithium clearance falls with age; lower target levels and slower titration are appropriate.22
Perinatal patients
- Pregnancy alters the differential (postpartum thyroiditis, autoimmune flares, eclampsia-related encephalopathy) and constrains pharmacotherapy.19
- Valproate is contraindicated in pregnancy due to neural tube defects and neurodevelopmental harm; carbamazepine is also teratogenic.19
- Lithium carries a smaller absolute risk of cardiac malformations than previously believed but still requires informed risk-benefit discussion and serum-level monitoring across the trimesters.19
- ECT is considered relatively safe in pregnancy when severe symptoms warrant it.23
Comorbid medical illness
- HIV-associated mania may respond to optimization of antiretroviral therapy with CNS-penetrant regimens, in addition to symptomatic mood treatment.11
- Multiple sclerosis-related mood elevation requires coordination with neurology around disease-modifying therapy and corticosteroid courses, which themselves can drive mood syndromes.5
- Post-stroke and post-TBI patients tolerate medications less well; start low, go slow, and reassess frequently.3-4
Comorbid substance use
- Substance use can both produce a substance/medication-induced bipolar disorder and unmask a medical cause; the differential should be revisited as substances clear.12
- Stimulant, cannabis, and synthetic cannabinoid use are increasingly identified precipitants in young adults presenting with first-episode mania.14
Cultural considerations
- HLA-B*1502 screening before carbamazepine in patients of Han Chinese, Thai, and other Southeast Asian ancestry is recommended to reduce risk of Stevens-Johnson syndrome.24
- Stigma around medical and psychiatric diagnoses varies across cultures and shapes both presentation and adherence; framing the diagnosis as a medical illness with mood manifestations is often clinically helpful.1
Outcome tracks the underlying medical illness more than the mood phenotype. Reversible causes carry the best prognosis; progressive neurodegenerative causes the worst.1,7
Course determinants
- Mood symptoms often remit when the underlying medical condition is treated, particularly in endocrine, infectious, and autoimmune cases.1,9-10
- Lesion-based etiologies (stroke, TBI) tend toward a single episode with gradual recovery, though residual irritability and disinhibition can persist.3-4
- Multiple sclerosis-related mood episodes can recur with relapses; frontotemporal dementia produces progressive behavioral disturbance rather than discrete episodes.5,16
Functional and mortality outcomes
- Functional outcome is dominated by the cognitive and physical sequelae of the underlying illness rather than by mood relapse alone.7
- Mortality is increased compared to the general population, reflecting the underlying medical condition; mortality data specific to the mood syndrome are limited.1
- Suicide risk is elevated during active mixed and depressive phases and warrants ongoing assessment, even when the manic phase has resolved.14
Acute presentations often combine agitation, medical instability, and impaired capacity, and they require coordinated medical and psychiatric management on a unit equipped for both. Disposition decisions should weigh the medical severity of the underlying condition alongside the psychiatric phenomenology.1,15
Indications for hospitalization
- Acute mania with risk of harm to self or others, inability to care for self, or psychotic features warrants inpatient admission.14
- A medical setting (medicine, neurology, or medical-psychiatric unit) is preferred when the underlying medical illness requires active workup or treatment, rather than a stand-alone psychiatric unit.1
Suicide risk
- Mixed states, comorbid depression, recent diagnosis of a serious medical illness, and prior attempts each increase risk and warrant repeated assessment.14
- Standardized screening with structured tools should support, not replace, clinical judgment.14
Do not use suicide-risk screening scales as a substitute for clinical judgment; a low score does not rule out imminent risk in a patient with active psychosis, agitation, or rapidly evolving medical illness.14
Agitation management
- Verbal de-escalation and environmental modification are first-line.15
- When pharmacologic intervention is needed, intramuscular options include haloperidol with or without lorazepam, or olanzapine; avoid combining IM olanzapine with parenteral benzodiazepines because of cardiorespiratory risk.15
- Intramuscular lorazepam alone is appropriate when the etiology of agitation is unclear or in alcohol-withdrawal contexts.15
Safety-relevant comorbidities
- Untreated infection, hypoxia, hypoglycemia, and electrolyte derangement can present as agitation or mania; the airway-breathing-circulation-glucose-vitals workup precedes psychiatric pharmacotherapy.15
- Acute neurologic events (intracranial hemorrhage, status epilepticus, autoimmune encephalitis) require neurology and emergency consultation in parallel with psychiatric stabilization.10,15
Several aspects of this diagnosis remain contested, both nosologically and therapeutically. The lack of randomized data is the through-line.1,21
Open questions
- Whether bipolar disorder due to another medical condition should remain a unitary diagnosis or be split by underlying mechanism (lesion-based, autoimmune, endocrine) is debated, with some authors arguing that mechanism-specific phenotypes warrant separate management algorithms.1,7
- The boundary with substance/medication-induced bipolar disorder is sometimes blurred, particularly for corticosteroid-induced mania occurring in the context of an autoimmune flare; DSM-5-TR places these under the substance/medication-induced category, but clinically the distinction can be artificial.12
- Whether antidepressants given during a depressive phase of a secondary mood syndrome carry the same switch risk as in primary bipolar disorder is uncertain; cautious extrapolation from primary bipolar guidelines is current practice.14
- Optimal duration of antimanic treatment after resolution of the underlying medical cause is not established.1,21
- Pharmacogenetic testing beyond HLA-B*1502 has not yet shown clear clinical utility in this population.24
Emerging considerations
- Recognition of autoimmune encephalitis (anti-NMDA receptor and related syndromes) as a cause of new-onset mania has expanded over the past decade and has reshaped the workup of atypical first-episode presentations.10
- Long COVID and post-acute sequelae of SARS-CoV-2 infection have been associated with neuropsychiatric syndromes including mania in case reports; the magnitude and mechanism remain under investigation.26
- Bipolar disorder due to another medical condition requires a prominent and persistent mood disturbance directly caused by an identifiable medical illness, not better explained by another disorder, and not occurring exclusively during delirium.12
- Substance- and medication-induced cases (including corticosteroid-induced mania) are coded separately as substance/medication-induced bipolar and related disorder.12
- ICD-11 codes the same construct under 6A60.4, secondary mood syndrome with manic symptoms.13
- New-onset mania after age 50 with no prior mood history should prompt a structured medical and neurologic workup before being labeled primary bipolar disorder.1,6
- Right orbitofrontal, basotemporal, and right-sided subcortical lesions are classically associated with secondary mania in stroke and TBI cohorts.3-4
- Recurrent culprits include stroke, TBI, multiple sclerosis, hyperthyroidism, Cushing syndrome, HIV, neurosyphilis, and autoimmune encephalitis.1,9-11
- Lithium has a narrow therapeutic window of 0.6-1.2 mEq/L for maintenance and is renally cleared, with caution warranted in CNS injury and unstable fluid status.19,22
- Valproate is often preferred over lithium in post-stroke and post-TBI mania because of tolerability, with monitoring for hepatotoxicity and thrombocytopenia.4,21
- HLA-B*1502 screening before carbamazepine initiation is recommended in patients of Asian ancestry to reduce Stevens-Johnson syndrome risk.24
- Antidepressants should generally be discontinued during the manic phase regardless of etiology.14
- ECT is effective in severe, refractory, or pharmacologically constrained cases of secondary mania.23
- Hyperactive delirium is the most commonly missed alternative diagnosis on medical wards.15
- Frontotemporal dementia can mimic secondary mania with disinhibition and impulsivity; insidious onset and progressive cognitive decline differentiate it.16
- Anti-NMDA receptor encephalitis can present with mania, psychosis, and dyskinesias; CSF studies and autoimmune panels are diagnostic.10
No external funding. No conflicts of interest declared. Peer-review status: pending.
References
- 1.Krauthammer C, Klerman GL. Secondary mania: manic syndromes associated with antecedent physical illness or drugs. Arch Gen Psychiatry. 1978;35(11):1333-1339.
- 2.Brooks JO, Hoblyn JC. Secondary mania in older adults. Am J Psychiatry. 2005;162(11):2033-2038.
- 3.Robinson RG, Boston JD, Starkstein SE, Price TR. Comparison of mania and depression after brain injury: causal factors. Am J Psychiatry. 1988;145(2):172-178.
- 4.Jorge RE, Robinson RG, Starkstein SE, Arndt SV, Forrester AW, Geisler FH. Secondary mania following traumatic brain injury. Am J Psychiatry. 1993;150(6):916-921.
- 5.Systematic reviewMarrie RA, Reingold S, Cohen J, et al. The incidence and prevalence of psychiatric disorders in multiple sclerosis: a systematic review. Mult Scler. 2015;21(3):305-317.
- 6.Tohen M, Shulman KI, Satlin A. First-episode mania in late life. Am J Psychiatry. 1994;151(1):130-132.
- 7.TextbookCummings JL, Mega MS. Neuropsychiatry and Behavioral Neuroscience. New York: Oxford University Press; 2003.
- 8.TextbookStahl SM. Stahl's Essential Psychopharmacology: Neuroscientific Basis and Practical Applications. 5th ed. Cambridge: Cambridge University Press; 2021.
- 9.Sonino N, Fava GA. Psychiatric disorders associated with Cushing's syndrome: epidemiology, pathophysiology and treatment. CNS Drugs. 2001;15(5):361-373.
- 10.Graus F, Titulaer MJ, Balu R, et al. A clinical approach to diagnosis of autoimmune encephalitis. Lancet Neurol. 2016;15(4):391-404.
- 11.Lyketsos CG, Schwartz J, Fishman M, Treisman G. AIDS mania. J Neuropsychiatry Clin Neurosci. 1997;9(2):277-279.
- 12.TextbookAmerican Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 5th ed, text rev. Washington, DC: American Psychiatric Association Publishing; 2022.
- 13.TextbookWorld Health Organization. ICD-11 for Mortality and Morbidity Statistics. Geneva: World Health Organization; 2019.
- 14.GuidelineYatham LN, Kennedy SH, Parikh SV, et al. Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) 2018 guidelines for the management of patients with bipolar disorder. Bipolar Disord. 2018;20(2):97-170.
- 15.TextbookAmerican Psychiatric Association. The American Psychiatric Publishing Textbook of Psychiatry. 7th ed. Washington, DC: American Psychiatric Association Publishing; 2019.
- 16.Rascovsky K, Hodges JR, Knopman D, et al. Sensitivity of revised diagnostic criteria for the behavioural variant of frontotemporal dementia. Brain. 2011;134(Pt 9):2456-2477.
- 17.TextbookSadock BJ, Sadock VA, Ruiz P. Kaplan and Sadock's Synopsis of Psychiatry. 11th ed. Philadelphia: Wolters Kluwer; 2015.
- 18.Nasreddine ZS, Phillips NA, Bedirian V, et al. The Montreal Cognitive Assessment, MoCA: a brief screening tool for mild cognitive impairment. J Am Geriatr Soc. 2005;53(4):695-699.
- 19.TextbookSchatzberg AF, DeBattista C. Schatzberg's Manual of Clinical Psychopharmacology. 9th ed. Washington, DC: American Psychiatric Association Publishing; 2019.
- 20.Young RC, Biggs JT, Ziegler VE, Meyer DA. A rating scale for mania: reliability, validity and sensitivity. Br J Psychiatry. 1978;133:429-435.
- 21.TextbookGoodwin FK, Jamison KR. Manic-Depressive Illness: Bipolar Disorders and Recurrent Depression. 2nd ed. New York: Oxford University Press; 2007.
- 22.Taylor DM, Barnes TRE, Young AH. The Maudsley Prescribing Guidelines in Psychiatry. 14th ed. Hoboken: Wiley-Blackwell; 2021.
- 23.American Psychiatric Association. The Practice of Electroconvulsive Therapy: Recommendations for Treatment, Training, and Privileging. 2nd ed. Washington, DC: American Psychiatric Association; 2001.
- 24.Chung WH, Hung SI, Hong HS, et al. Medical genetics: a marker for Stevens-Johnson syndrome. Nature. 2004;428(6982):486.
- 25.RegulatoryUS Food and Drug Administration. FDA Public Health Advisory: Deaths with Antipsychotics in Elderly Patients with Behavioral Disturbances. Silver Spring: FDA; 2005.
- 26.CohortTaquet M, Geddes JR, Husain M, Luciano S, Harrison PJ. 6-month neurological and psychiatric outcomes in 236,379 survivors of COVID-19: a retrospective cohort study using electronic health records. Lancet Psychiatry. 2021;8(5):416-427.